Differential Effects of β-Blockers in Patients With Heart Failure
Why the study?
Does carvedilol improve cardiac performance more than metoprolol in patients with heart failure and LVEF <=0.35?
Population
150 patients with heart failure and left ventricular ejection fraction <=0.35
Comparison
Carvedilol (mean dose 49+/-18 mg/d) vs Metoprolol (mean dose 124+/-55 mg/d)
Design
RCT, randomized, double-blind
Follow-up
mean 23+/-11 months
Authors
Discussion
Loading...
Member takes
Implication
Clinicians may prefer carvedilol over metoprolol for LVEF gains in HFrEF; extends head-to-head RCT data on beta-blocker selection.
Structured PICO
Does carvedilol improve cardiac performance more than metoprolol in patients with heart failure and LVEF <=0.35?
P
Population
150 patients with heart failure and left ventricular ejection fraction <=0.35
I
Intervention
Carvedilol (mean dose 49+/-18 mg/d)
C
Comparator
Metoprolol (mean dose 124+/-55 mg/d)
O
Outcome
Change in left ventricular ejection fraction at rest after 13 to 15 months of treatmentsurrogate
Carvedilol improves cardiac performance and hemodynamics to a greater extent than metoprolol in patients with heart failure, likely due to its greater antiadrenergic activity.
Cite This Study
Metra et al. (2000) studied this question.